Technical Analysis for GBT - Global Blood Therapeutics, Inc.

Grade Last Price % Change Price Change
F 27.73 -1.70% -0.48
GBT closed down 1.7 percent on Tuesday, July 27, 2021, on 83 percent of normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Aug 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical GBT trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New Downtrend Bearish 0.00%
Hammer Candlestick Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Older End-of-Day Signals for GBT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 13 hours ago
Fell Below Lower Bollinger Band about 13 hours ago
Down 2 % about 13 hours ago
Down 1% about 14 hours ago
Fell Below Previous Day's Low about 14 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hemoglobin Blood Angioedema Hereditary Angioedema Sickle Cell Disease Hemoglobins Pulmonary Disorders

Is GBT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 71.23
52 Week Low 27.1
Average Volume 1,086,974
200-Day Moving Average 43.17
50-Day Moving Average 35.73
20-Day Moving Average 32.36
10-Day Moving Average 30.36
Average True Range 1.46
ADX 25.77
+DI 11.87
-DI 39.22
Chandelier Exit (Long, 3 ATRs) 33.22
Chandelier Exit (Short, 3 ATRs) 31.47
Upper Bollinger Bands 37.39
Lower Bollinger Band 27.34
Percent B (%b) 0.04
BandWidth 31.04
MACD Line -2.18
MACD Signal Line -1.77
MACD Histogram -0.4113
Fundamentals Value
Market Cap 1.71 Billion
Num Shares 61.8 Million
EPS -3.65
Price-to-Earnings (P/E) Ratio -7.61
Price-to-Sales 32.35
Price-to-Book 6.06
PEG Ratio -0.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.29
Resistance 3 (R3) 29.25 28.70 29.03
Resistance 2 (R2) 28.70 28.30 28.72 28.94
Resistance 1 (R1) 28.21 28.05 27.94 28.25 28.86
Pivot Point 27.66 27.66 27.52 27.68 27.66
Support 1 (S1) 27.17 27.26 26.90 27.21 26.60
Support 2 (S2) 26.62 27.01 26.64 26.52
Support 3 (S3) 26.13 26.62 26.43
Support 4 (S4) 26.17